autologous dendritic cells transduced with wild-type p53 adenovirus vaccine

A cancer vaccine consisting of autologous dendritic cells (DCs) transduced with a recombinant replication-defective adenoviral (Ad) vector encoding the full-length wild-type (wt) cancer tumor antigen p53 protein (TP53; p53), with potential immunomodulating activity. Intradermal vaccination with the autologous DCs transduced with wt p53 Ad vaccine may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells overexpressing wt and mutant forms of p53, resulting in tumor cell lysis. p53, a tumor suppressor gene, is overexpressed and/or mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation.